Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immunome, Inc. - Common Stock
(NQ:
IMNM
)
21.35
-0.15 (-0.70%)
Streaming Delayed Price
Updated: 12:08 PM EST, Feb 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunome, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Immunome to Present at Upcoming Investor Conferences
Today 8:00 EST
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2026
From
Immunome, Inc.
Via
Business Wire
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 05, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Pricing of Public Offering of Common Stock
December 16, 2025
From
Immunome, Inc.
Via
Business Wire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Immunome Announces Proposed Public Offering of Common Stock
December 15, 2025
From
Immunome, Inc.
Via
Business Wire
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
December 15, 2025
Via
AB Newswire
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
December 15, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
December 14, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Upcoming Investor Conferences
November 25, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
October 31, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
October 23, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From
Immunome, Inc.
Via
Business Wire
Infinimmune Announces Research Collaboration with Immunome
September 18, 2025
From
Infinimmune
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
August 06, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Upcoming Investor Conferences
May 22, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
April 04, 2025
From
Immunome, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
